A double-blind placebo-controlled trial of azithromycin to reduce mortality and improve growth in high-risk young children with non-bloody diarrhoea in low resource settings: the Antibiotics for Children with Diarrhoea (ABCD) trial protocol
Background Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of a...
Uložené v:
| Vydané v: | Current controlled trials in cardiovascular medicine Ročník 21; číslo 1; s. 71 - 10 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
13.01.2020
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1745-6215, 1745-6215 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention.
Methods
ABCD is a double-blind, randomised trial recruiting 11,500 children aged 2–23 months presenting with acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment.
Discussion
Expanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines.
Trial registration
Clinicaltrials.gov,
NCT03130114
. Registered on April 26 2017. |
|---|---|
| AbstractList | BackgroundAcute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention.MethodsABCD is a double-blind, randomised trial recruiting 11,500 children aged 2–23 months presenting with acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment.DiscussionExpanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines.Trial registrationClinicaltrials.gov, NCT03130114. Registered on April 26 2017. Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention.BACKGROUNDAcute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention.ABCD is a double-blind, randomised trial recruiting 11,500 children aged 2-23 months presenting with acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment.METHODSABCD is a double-blind, randomised trial recruiting 11,500 children aged 2-23 months presenting with acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment.Expanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines.DISCUSSIONExpanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines.Clinicaltrials.gov, NCT03130114. Registered on April 26 2017.TRIAL REGISTRATIONClinicaltrials.gov, NCT03130114. Registered on April 26 2017. Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention. ABCD is a double-blind, randomised trial recruiting 11,500 children aged 2-23 months presenting with acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment. Expanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines. Clinicaltrials.gov, NCT03130114. Registered on April 26 2017. Background Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention. Methods ABCD is a double-blind, randomised trial recruiting 11,500 children aged 2–23 months presenting with acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment. Discussion Expanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines. Trial registration Clinicaltrials.gov, NCT03130114 . Registered on April 26 2017. Abstract Background Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention. Methods ABCD is a double-blind, randomised trial recruiting 11,500 children aged 2–23 months presenting with acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment. Discussion Expanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines. Trial registration Clinicaltrials.gov, NCT03130114. Registered on April 26 2017. Background Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention. Methods ABCD is a double-blind, randomised trial recruiting 11,500 children aged 2-23 months presenting with acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment. Discussion Expanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines. Trial registration Clinicaltrials.gov, NCT03130114. Registered on April 26 2017. Keywords: Antibiotics, Azithromycin, Paediatric diarrhoea, Mortality, Growth, Randomised Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical management of acute watery diarrhoea in children focus on oral rehydration, supplemental zinc and feeding advice. Routine use of antibiotics is not recommended except when diarrhoea is bloody or cholera is suspected. Young children who are undernourished or have a dehydrating diarrhoea are more susceptible to death at 90 days after onset of diarrhoea. Given the mortality risk associated with diarrhoea in children with malnutrition or dehydrating diarrhoea, expanding the use of antibiotics for this subset of children could be an important intervention to reduce diarrhoea-associated mortality and morbidity. We designed the Antibiotics for Childhood Diarrhoea (ABCD) trial to test this intervention. ABCD is a double-blind, randomised trial recruiting 11,500 children aged 2-23 months presenting with acute non-bloody diarrhoea who are dehydrated and/or undernourished (i.e. have a high risk for mortality). Enrolled children in Bangladesh, India, Kenya, Malawi, Mali, Pakistan and Tanzania are randomised (1:1) to oral azithromycin 10 mg/kg or placebo once daily for 3 days and followed-up for 180 days. Primary efficacy endpoints are all-cause mortality during the 180 days post-enrolment and change in linear growth 90 days post-enrolment. Expanding the treatment of acute watery diarrhoea in high-risk children to include an antibiotic may offer an opportunity to reduce deaths. These benefits may result from direct antimicrobial effects on pathogens or other incompletely understood mechanisms including improved nutrition, alterations in immune responsiveness or improved enteric function. The expansion of indications for antibiotic use raises concerns about the emergence of antimicrobial resistance both within treated children and the communities in which they live. ABCD will monitor antimicrobial resistance. The ABCD trial has important policy implications. If the trial shows significant benefits of azithromycin use, this may provide evidence to support reconsideration of antibiotic indications in the present World Health Organization diarrhoea management guidelines. Conversely, if there is no evidence of benefit, these results will support the current avoidance of antibiotics except in dysentery or cholera, thereby avoiding inappropriate use of antibiotics and reaffirming the current guidelines. |
| ArticleNumber | 71 |
| Audience | Academic |
| Author | Alam, T Dhingra, P Singa, B Badji, H Yousufzai, M. T Sharma, A. K Mehta, A Kotloff, K Manji, K De Costa, A Ndeketa, L Ashorn, P Bahl, R Deb, S Dhingra, U Malle, D Walson, J. L Freyne, B Qureshi, S Coulibaly, F Bar-Zeev, N Tapia, M Rahman, M. W Haidara, F Kibwana, U Okello, M Pavlinac, P. B Somji, S Chisti, M. J Nyabinda, C Kabir, F Dutta, A McGrath, C Bakari, M Kisenge, R Jaiswal, V. K Thobani, R Shakoor, S Dube, Q Asthana, A. K Duggan, C Sudfeld, C Booth, J. P Chouhan, A Ndamala, C Qamar, F Ahmed, T Sazawal, S Sow, S Tennant, S Ahmed, D Bansal, P. K Hotwani, A Kumar, J Simon, J Pandey, A |
| Author_xml | – sequence: 1 fullname: Alam, T – sequence: 2 fullname: Ahmed, D – sequence: 3 fullname: Ahmed, T – sequence: 4 fullname: Chisti, M. J – sequence: 5 fullname: Rahman, M. W – sequence: 6 fullname: Asthana, A. K – sequence: 7 fullname: Bansal, P. K – sequence: 8 fullname: Chouhan, A – sequence: 9 fullname: Deb, S – sequence: 10 fullname: Dhingra, P – sequence: 11 fullname: Dhingra, U – sequence: 12 fullname: Dutta, A – sequence: 13 fullname: Jaiswal, V. K – sequence: 14 fullname: Kumar, J – sequence: 15 fullname: Pandey, A – sequence: 16 fullname: Sazawal, S – sequence: 17 fullname: Sharma, A. K – sequence: 18 fullname: McGrath, C – sequence: 19 fullname: Nyabinda, C – sequence: 20 fullname: Okello, M – sequence: 21 fullname: Pavlinac, P. B – sequence: 22 fullname: Singa, B – sequence: 23 fullname: Walson, J. L – sequence: 24 fullname: Bar-Zeev, N – sequence: 25 fullname: Dube, Q – sequence: 26 fullname: Freyne, B – sequence: 27 fullname: Ndamala, C – sequence: 28 fullname: Ndeketa, L – sequence: 29 fullname: Badji, H – sequence: 30 fullname: Booth, J. P – sequence: 31 fullname: Coulibaly, F – sequence: 32 fullname: Haidara, F – sequence: 33 fullname: Kotloff, K – sequence: 34 fullname: Malle, D – sequence: 35 fullname: Mehta, A – sequence: 36 fullname: Sow, S – sequence: 37 fullname: Tapia, M – sequence: 38 fullname: Tennant, S – sequence: 39 fullname: Hotwani, A – sequence: 40 fullname: Kabir, F – sequence: 41 fullname: Qamar, F – sequence: 42 fullname: Qureshi, S – sequence: 43 fullname: Shakoor, S – sequence: 44 fullname: Thobani, R – sequence: 45 fullname: Yousufzai, M. T – sequence: 46 fullname: Bakari, M – sequence: 47 fullname: Duggan, C – sequence: 48 fullname: Kibwana, U – sequence: 49 fullname: Kisenge, R – sequence: 50 fullname: Manji, K – sequence: 51 fullname: Somji, S – sequence: 52 fullname: Sudfeld, C – sequence: 53 fullname: Ashorn, P – sequence: 54 fullname: Bahl, R – sequence: 55 fullname: De Costa, A – sequence: 56 fullname: Simon, J |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31931848$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9U0tv1DAQjlARfcAP4IIscSmHFDvOk0OlZcujUiUucLYce5K4eDOL7bQKv5qfgJftayvglMj-HvONZw6TvRFHSJKXjJ4wVpdvPeO05CllTcrrrEnnJ8kBq_IiLTNW7D34308Ovb-kNOcNz58l-5w1nNV5fZD8WhCNU2shba0ZNVlbqaDFVOEYHFoLmgRnpCXYEfnThMHhalZmJAGJAz0pICt0QVoTZiKjgFmtHV4B6R1eh4FE5GD6IXXGfyczTmNP1GCsdjCS6yhHYqRojahnoo10bkCQG5bF62jgcXLRwkMIZuz9OxIGIIsxmNZgMMqTDh1Z7gie3akcL94vz97c1B-rCqjQPk-edtJ6eHHzPUq-ffzwdfk5vfjy6Xy5uEhVWfGQZiUtoKG6lKB41tVKSQ2M8ybLKl41bbzKQReq4AryvKugaFRTVloBrSnkJT9Kzre6GuWlWDuzkm4WKI34c4CuF9LFCBaEbmUu66btoKhyWTUyk7rmJaWU11RLHbVOt1rrqV1B9IhvI-2O6O7NaAbR45Uom6LMqzoKHN8IOPwxgQ9iZbwCa-UIOHmR8ejUsLJgEfr6EfQyvsEYWyVicspzSuviHtXLGMCMHUZftREVi5KxrMrqWP1RcvIXlNy0cmXihEFn4vkO4dXDoHcJb-c1AqotQDn03kEnlAkymM20SmMFo2KzGWK7GSJuhthshpgjkz1i3or_j5NtOT5ixx7cfS_-TfoNBUEl6g |
| CitedBy_id | crossref_primary_10_1136_bmjpo_2023_002448 crossref_primary_10_1111_ijpo_12727 crossref_primary_10_1136_bmjgh_2024_018337 crossref_primary_10_1093_jpids_piab080 crossref_primary_10_1093_ofid_ofad651 crossref_primary_10_1093_ofid_ofad586 crossref_primary_10_7189_jogh_15_04185 crossref_primary_10_3390_nu14091935 crossref_primary_10_1016_j_ijantimicag_2021_106364 crossref_primary_10_1001_jamanetworkopen_2021_36726 crossref_primary_10_7189_jogh_14_04196 crossref_primary_10_1093_infdis_jiad252 crossref_primary_10_1371_journal_pone_0249569 crossref_primary_10_1111_mcn_13547 |
| Cites_doi | 10.1371/journal.pone.0207743 10.1056/NEJMoa1817213 10.1016/S0140-6736(13)60844-2 10.1185/03007995.2011.639355 10.1056/NEJMoa1811400 10.1056/NEJMoa1715474 10.1093/jpids/piv028 10.1016/S1473-3099(18)30362-1 10.7189/jogh.06.010603 10.1093/jpids/piv037 10.1016/S0140-6736(13)60319-0 10.1001/jama.2009.1266 10.2471/BLT.16.176123 10.1136/bmj.38049.490255.DE 10.1093/ije/dyu062 10.1038/s41598-017-06862-0 |
| ContentType | Journal Article |
| Contributor | Alam, T Rahman, M W Dhingra, P Singa, B Bansal, P K Badji, H Asthana, A K Mehta, A Kotloff, K Manji, K De Costa, A Pavlinac, P B Ndeketa, L Ashorn, P Bahl, R Deb, S Dhingra, U Malle, D Freyne, B Jaiswal, V K Qureshi, S Coulibaly, F Bar-Zeev, N Tapia, M Haidara, F Kibwana, U Yousufzai, M T Okello, M Booth, J P Somji, S Nyabinda, C Kabir, F Dutta, A McGrath, C Bakari, M Kisenge, R Sharma, A K Thobani, R Shakoor, S Dube, Q Duggan, C Sudfeld, C Chouhan, A Ndamala, C Qamar, F Walson, J L Ahmed, T Sazawal, S Sow, S Tennant, S Ahmed, D Chisti, M J Hotwani, A Kumar, J Simon, J Pandey, A |
| Contributor_xml | – sequence: 1 givenname: T surname: Alam fullname: Alam, T – sequence: 2 givenname: D surname: Ahmed fullname: Ahmed, D – sequence: 3 givenname: T surname: Ahmed fullname: Ahmed, T – sequence: 4 givenname: M J surname: Chisti fullname: Chisti, M J – sequence: 5 givenname: M W surname: Rahman fullname: Rahman, M W – sequence: 6 givenname: A K surname: Asthana fullname: Asthana, A K – sequence: 7 givenname: P K surname: Bansal fullname: Bansal, P K – sequence: 8 givenname: A surname: Chouhan fullname: Chouhan, A – sequence: 9 givenname: S surname: Deb fullname: Deb, S – sequence: 10 givenname: P surname: Dhingra fullname: Dhingra, P – sequence: 11 givenname: U surname: Dhingra fullname: Dhingra, U – sequence: 12 givenname: A surname: Dutta fullname: Dutta, A – sequence: 13 givenname: V K surname: Jaiswal fullname: Jaiswal, V K – sequence: 14 givenname: J surname: Kumar fullname: Kumar, J – sequence: 15 givenname: A surname: Pandey fullname: Pandey, A – sequence: 16 givenname: S surname: Sazawal fullname: Sazawal, S – sequence: 17 givenname: A K surname: Sharma fullname: Sharma, A K – sequence: 18 givenname: C surname: McGrath fullname: McGrath, C – sequence: 19 givenname: C surname: Nyabinda fullname: Nyabinda, C – sequence: 20 givenname: M surname: Okello fullname: Okello, M – sequence: 21 givenname: P B surname: Pavlinac fullname: Pavlinac, P B – sequence: 22 givenname: B surname: Singa fullname: Singa, B – sequence: 23 givenname: J L surname: Walson fullname: Walson, J L – sequence: 24 givenname: N surname: Bar-Zeev fullname: Bar-Zeev, N – sequence: 25 givenname: Q surname: Dube fullname: Dube, Q – sequence: 26 givenname: B surname: Freyne fullname: Freyne, B – sequence: 27 givenname: C surname: Ndamala fullname: Ndamala, C – sequence: 28 givenname: L surname: Ndeketa fullname: Ndeketa, L – sequence: 29 givenname: H surname: Badji fullname: Badji, H – sequence: 30 givenname: J P surname: Booth fullname: Booth, J P – sequence: 31 givenname: F surname: Coulibaly fullname: Coulibaly, F – sequence: 32 givenname: F surname: Haidara fullname: Haidara, F – sequence: 33 givenname: K surname: Kotloff fullname: Kotloff, K – sequence: 34 givenname: D surname: Malle fullname: Malle, D – sequence: 35 givenname: A surname: Mehta fullname: Mehta, A – sequence: 36 givenname: S surname: Sow fullname: Sow, S – sequence: 37 givenname: M surname: Tapia fullname: Tapia, M – sequence: 38 givenname: S surname: Tennant fullname: Tennant, S – sequence: 39 givenname: A surname: Hotwani fullname: Hotwani, A – sequence: 40 givenname: F surname: Kabir fullname: Kabir, F – sequence: 41 givenname: F surname: Qamar fullname: Qamar, F – sequence: 42 givenname: S surname: Qureshi fullname: Qureshi, S – sequence: 43 givenname: S surname: Shakoor fullname: Shakoor, S – sequence: 44 givenname: R surname: Thobani fullname: Thobani, R – sequence: 45 givenname: M T surname: Yousufzai fullname: Yousufzai, M T – sequence: 46 givenname: M surname: Bakari fullname: Bakari, M – sequence: 47 givenname: C surname: Duggan fullname: Duggan, C – sequence: 48 givenname: U surname: Kibwana fullname: Kibwana, U – sequence: 49 givenname: R surname: Kisenge fullname: Kisenge, R – sequence: 50 givenname: K surname: Manji fullname: Manji, K – sequence: 51 givenname: S surname: Somji fullname: Somji, S – sequence: 52 givenname: C surname: Sudfeld fullname: Sudfeld, C – sequence: 53 givenname: P surname: Ashorn fullname: Ashorn, P – sequence: 54 givenname: R surname: Bahl fullname: Bahl, R – sequence: 55 givenname: A surname: De Costa fullname: De Costa, A – sequence: 56 givenname: J surname: Simon fullname: Simon, J |
| Copyright | The Author(s). 2020 COPYRIGHT 2020 BioMed Central Ltd. The Author(s). 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: The Author(s). 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | The ABCD study team ABCD study team |
| CorporateAuthor_xml | – name: The ABCD study team – name: ABCD study team |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-019-3829-y |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7RV name: Nursing & allied health premium. url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1745-6215 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_dba4a89bfe574a79a2ad836000380dad PMC6956478 A611272800 31931848 10_1186_s13063_019_3829_y |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | Africa South of the Sahara Asia, Western Bangladesh Pakistan Kenya Malawi India |
| GeographicLocations_xml | – name: Africa South of the Sahara – name: Asia, Western – name: Malawi – name: Bangladesh – name: Kenya – name: India – name: Pakistan |
| GrantInformation_xml | – fundername: Bill and Melinda Gates Foundation grantid: OPP1126331 funderid: http://dx.doi.org/10.13039/100000865 – fundername: Wellcome Trust – fundername: ; grantid: OPP1126331 |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
| ID | FETCH-LOGICAL-c673t-2605e90d6aec32f8ccade1339227379b90d4ed5c53ce44f7e59c967dce080e463 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 17 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000514654000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1745-6215 |
| IngestDate | Tue Oct 14 19:08:26 EDT 2025 Tue Nov 04 01:52:20 EST 2025 Sun Nov 09 14:16:38 EST 2025 Sun Oct 19 01:28:07 EDT 2025 Tue Nov 11 09:53:04 EST 2025 Tue Nov 04 17:59:36 EST 2025 Mon Jul 21 06:04:57 EDT 2025 Sat Nov 29 06:09:33 EST 2025 Tue Nov 18 22:48:28 EST 2025 Sat Sep 06 07:26:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Antibiotics Randomised Growth Paediatric diarrhoea Mortality Azithromycin |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c673t-2605e90d6aec32f8ccade1339227379b90d4ed5c53ce44f7e59c967dce080e463 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1186/s13063-019-3829-y |
| PMID | 31931848 |
| PQID | 2730340085 |
| PQPubID | 44365 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_dba4a89bfe574a79a2ad836000380dad pubmedcentral_primary_oai_pubmedcentral_nih_gov_6956478 proquest_miscellaneous_2338091651 proquest_journals_2730340085 gale_infotracmisc_A611272800 gale_infotracacademiconefile_A611272800 pubmed_primary_31931848 crossref_citationtrail_10_1186_s13063_019_3829_y crossref_primary_10_1186_s13063_019_3829_y springer_journals_10_1186_s13063_019_3829_y |
| PublicationCentury | 2000 |
| PublicationDate | 2020-01-13 |
| PublicationDateYYYYMMDD | 2020-01-13 |
| PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | EPK Parker (3829_CR18) 2017; 7 GBD 2016 Diarrhoeal Diseases Collaborators (3829_CR1) 2018; 18 PB Pavlinac (3829_CR6) 2016; 5 TC Porco (3829_CR11) 2009; 302 World Health Organization (3829_CR14) 2013 ET Rogawski (3829_CR22) 2017; 95 KL Kotloff (3829_CR4) 2013; 382 JM Pernica (3829_CR7) 2016; 5 3829_CR5 JD Keenan (3829_CR12) 2018; 378 3829_CR2 JD Keenan (3829_CR13) 2019; 380 AK Koffi (3829_CR19) 2016; 6 D Chandramohan (3829_CR21) 2019; 380 ISCAP Study Group (3829_CR23) 2004; 328 C Jennison (3829_CR20) 2000 World Health Organization (3829_CR10) 2019 M Chopra (3829_CR3) 2013; 381 JC Seidman (3829_CR17) 2014; 43 AL Rice (3829_CR8) 2000; 78 AG Wasihun (3829_CR9) 2018; 13 3829_CR15 AK Lakoš (3829_CR16) 2012; 28 |
| References_xml | – volume: 13 start-page: e0207743 issue: 11 year: 2018 ident: 3829_CR9 publication-title: PLoS One doi: 10.1371/journal.pone.0207743 – ident: 3829_CR15 – volume: 380 start-page: 2207 year: 2019 ident: 3829_CR13 publication-title: N Engl J Med doi: 10.1056/NEJMoa1817213 – volume: 382 start-page: 209 issue: 9888 year: 2013 ident: 3829_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(13)60844-2 – volume: 28 start-page: 155 issue: 1 year: 2012 ident: 3829_CR16 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2011.639355 – volume: 380 start-page: 2197 year: 2019 ident: 3829_CR21 publication-title: N Engl J Med doi: 10.1056/NEJMoa1811400 – volume: 378 start-page: 1583 year: 2018 ident: 3829_CR12 publication-title: N Engl J Med doi: 10.1056/NEJMoa1715474 – volume: 5 start-page: 312 issue: 3 year: 2016 ident: 3829_CR7 publication-title: J Pediatric Infect Dis Soc doi: 10.1093/jpids/piv028 – volume: 18 start-page: 1211 year: 2018 ident: 3829_CR1 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(18)30362-1 – volume-title: Pocket book of hospital care for children. Guidelines for the management of common childhood illnesses year: 2013 ident: 3829_CR14 – volume: 6 start-page: 010603 issue: 1 year: 2016 ident: 3829_CR19 publication-title: J Glob Health doi: 10.7189/jogh.06.010603 – volume: 5 start-page: 366 issue: 4 year: 2016 ident: 3829_CR6 publication-title: J Pediatric Infect Dis Soc doi: 10.1093/jpids/piv037 – volume: 381 start-page: 1499 issue: 9876 year: 2013 ident: 3829_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(13)60319-0 – ident: 3829_CR5 – ident: 3829_CR2 – volume: 78 start-page: 1207 year: 2000 ident: 3829_CR8 publication-title: Bull World Health Organ – volume: 302 start-page: 962 year: 2009 ident: 3829_CR11 publication-title: JAMA doi: 10.1001/jama.2009.1266 – volume-title: Group sequential methods with applications to clinical trials year: 2000 ident: 3829_CR20 – volume: 95 start-page: 49 issue: 1 year: 2017 ident: 3829_CR22 publication-title: Bull World Health Organ doi: 10.2471/BLT.16.176123 – volume: 328 start-page: 791 issue: 7443 year: 2004 ident: 3829_CR23 publication-title: BMJ doi: 10.1136/bmj.38049.490255.DE – volume: 43 start-page: 1105 year: 2014 ident: 3829_CR17 publication-title: Int J Epidemiol doi: 10.1093/ije/dyu062 – volume: 7 start-page: 9168 issue: 1 year: 2017 ident: 3829_CR18 publication-title: Sci Rep doi: 10.1038/s41598-017-06862-0 – volume-title: Report of the 20th meeting of the WHO alliance for the global elimination of trachoma by 2020 Sydney, Australia year: 2019 ident: 3829_CR10 |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.3118057 |
| Snippet | Background
Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for... Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the clinical... Background Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for... BackgroundAcute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization guidelines for the... Abstract Background Acute diarrhoea is a common cause of illness and death among children in low- to middle-income settings. World Health Organization... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 71 |
| SubjectTerms | Africa South of the Sahara Age Factors Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antibiotics Antimicrobial agents Asia, Western Azithromycin Azithromycin - adverse effects Azithromycin - therapeutic use Bacterial infections Biomedicine Caregivers Child Development Child health Childhood Children Children & youth Cholera Clinical trials Community Consent Death Dehydration - diagnosis Dehydration - mortality Dehydration - physiopathology Developing Countries Diarrhea Diarrhea - diagnosis Diarrhea - drug therapy Diarrhea - mortality Diarrhea - physiopathology Double-Blind Method Double-blind studies Drug resistance Dysentery Etiology Female Growth Health aspects Health facilities Health Sciences Humans Infant Infant Mortality Infant Nutrition Disorders - diagnosis Infant Nutrition Disorders - mortality Infant Nutrition Disorders - physiopathology Infant Nutritional Physiological Phenomena Low income groups Male Malnutrition Malnutrition - diagnosis Malnutrition - mortality Malnutrition - physiopathology Medicine Medicine & Public Health Microbial drug resistance Morbidity Mortality Multicenter Studies as Topic Nutrition Nutritional Status Organism Hydration Status Paediatric diarrhoea Pathogenic microorganisms Pathogens Pediatrics Public health Randomised Randomized Controlled Trials as Topic Retirement benefits Risk Assessment Risk Factors Statistics for Life Sciences Streptococcus infections Study Protocol Time Factors Treatment Outcome Water-Electrolyte Balance Womens health |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQCiEuiDeBBQ0SEi9ZmyaOY3PrdllxgBUHkPZmObazrdRNUB-g8qv5Ccw4adksAi5c60f9-PJ5xjOeYewZXU1kSjpeBdRVhdCeW2kDFyoUwVuEiY0h89-XJyfq9FR_vJDqi3zCuvDA3cId-MoKq3RVh6IUttQ2s54eHpBJK_XWE_ui1LNVpjoOxlM2F70Nc6TkwRKZmuyVI81zlWm-GZxCMVj_75R84Uy67C95yWgaz6Ljm-xGL0TCuBv8LXYlNLfZtQ-9mfwO-zEG366reeAVSpEeouNV1fLeL30ePMRsHdDWYL_PKFXC-QabwqqFBcVyDXAexXIU0cFiB7N49RDgDJX21RSwJoU55uSXDhviC9g-Cge62IWmbXh0id8A4m-xmLbBUqt5-w3_oDMYwDJEn-vlG0AhFMYNvV5pKWo0oCANk0GHR7teXowPJ0cv-_FTlIkWoXyXfT5--2nyjvepHbiTZb7ipEUFnXqEhcuzWjl6DIDqss5QnCp1hUUi-MIVuQtC1GUotNOyxB3AvQ5C5vfYHk4lPGAgQ610ijzppCOjZCVUXYtS-Tq3elRUCUu3W21cH_ec0m_MTdR_lDQdOgyiwxA6zCZhr3ZNvnRBP_5W-ZDws6tI8brjD4hi06PY_AvFCXtO6DPEKjg4Z_vHEThFis9lxhLlYsokliZsf1AT2cANi7f4NT0bLQ2uaZoLkq4T9nRXTC3Jw64J7Rrr5DgS1BWKUcLud3DfTQlpGqlfqISVgw9hMOdhSTObxljlEvVv3IyEvd5-Mr-G9cclffg_lvQRu57R3QhS0CjfZ3urxTo8Zlfd19VsuXgS6eInhPx0FA priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLagQwgJcRm3wEBGQgKGrLWJk9i8oHYX8QDVhEDaW-TYzlqpi0faMZVfzU_gHMftyBB74TW-xCc5_nxuPoeQV2iaiEWmWWlBV-VcGqYyZRkXNrVGAZsonzL_Uz4ei6MjeRgMbvMQVrnCRA_Uxmm0ke_AMdtPOEoIH06_M6wahd7VUELjOtnATGW8RzZG--PDL2s_Qi4yHnyZA5HtzAGx0W85kCwRsWTLzmnkk_b_Dc1_nE2X4yYvOU_9mXRw93-puUfuBGmUDlv2uU-u2XqT3Pwc_O2b5HZr1aPtZaUH5NeQGgePLIPHtaE-oqt0LAS8z6yhvgwIdRVVP6dYg-FkCVPRhaMNJom19MTL-yD7UwUTTL1Nw9Ljxp0vJhR6Yv5khgHvdIlARFe3zSlajGntauZj7ZcUGLtpJs4qHDVz5_CC1hNB59YHc8_fU5Bu6bDGazEO01FTkNDpbmfCvfUsb4aj3b23Yf2YvsLBHnlIvh3sf939yELNCKazPFkwVM-s7BvgN53EldB4ywD0cBnDJ89lCU3cmlSnibacV7lNpZZZDr8URGfLs-QR6QEp9gmhma2E7AMA60yjt7Pkoqp4LkyVKDlIy4j0V7xT6JBQHet6zAqvWImsaNmtAHYrkN2KZUS210NO22wiV3UeIUOuO2IicP_ANcdFwJXClIorIcvKpjlXuVSxMngvBz2-faNMRF4jOxcIV7A4rcKtCyARE38VwwwEbixR1o_IVqcnwIzuNq84uQgwNy8u2DgiL9fNOBJD92rrzqBPAisBJSQdRORxu3_WJAH-w5nCRUTyzs7q0NxtqacTnwQ9A8UefkZE3q324MWy_vlJn15NxDNyK0ZzCqDWINkivUVzZp-TG_rHYjpvXgRs-Q20VYeS priority: 102 providerName: ProQuest |
| Title | A double-blind placebo-controlled trial of azithromycin to reduce mortality and improve growth in high-risk young children with non-bloody diarrhoea in low resource settings: the Antibiotics for Children with Diarrhoea (ABCD) trial protocol |
| URI | https://link.springer.com/article/10.1186/s13063-019-3829-y https://www.ncbi.nlm.nih.gov/pubmed/31931848 https://www.proquest.com/docview/2730340085 https://www.proquest.com/docview/2338091651 https://pubmed.ncbi.nlm.nih.gov/PMC6956478 https://doaj.org/article/dba4a89bfe574a79a2ad836000380dad |
| Volume | 21 |
| WOSCitedRecordID | wos000514654000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RBZ dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: DOA dateStart: 20060101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: M~E dateStart: 20060101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7X7 dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & allied health premium. customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: 7RV dateStart: 20000401 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: BENPR dateStart: 20000401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: PIMPY dateStart: 20000401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1745-6215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0043934 issn: 1745-6215 databaseCode: RSV dateStart: 20000401 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zj9MwELbYXYR44T4CS2UkJC5ZpImT2Ly13V2BxFZVgVX3yXIcZ1upm6CmBZVfzU9gxk0KWQ4JXiK1PmLH429mPIcJeYJHE4GIDUst6Kqcy4zpWFvGhY1spoFMtEuZ_y4ZDsVkIkd1HHfVeLs3JkmH1G5bi_hVBWiLNseuZKEIJFvvkD3gdgJ34_j9SQO_wGBDXpsvf9usxYBcnv5f0fgndnTRVfKCvdSxoaPr_zWBG-RaLXXS3oZMbpJLtrhFrhzXdvXb5FuPZuUqnVuWQs8ZdZ5aaclqR_a5zai73oOWOdVfZ3i3wvkamtJlSReY_NXScyfHg0xPNXQwc2cVlp6Blr-cUqiJeZEZOrLTNQIMbaLIKZ4E06IsmPOhX1Mg2MViWlqNreblF3jBxsJAK-uctKvXFKRW2isw3KXENNMUJG86aHV4sO3lWa8_OHhejx_TUpRA-3fIx6PDD4M3rL4Lgpk4CZcM1S4r_QzoyIRBLgxGD4B-LQOQvxKZQhG3WWSi0FjO88RG0sg4gXUDkdjyOLxLdmEq9j6hsc2F9AFYTWzQiplykec8EVkeatmNUo_4DYEoUydKx_s65sopTCJWm5VUsJIKV1KtPfJi2-TTJkvI3yr3keq2FTHBt_ujXJypGi9UlmquhUxzGyVcJ1IHOsN4G7Tk-pnOPPIUaVYhDMHgjK6jKWCKmNBL9WIQpPHqMd8j-62aAB-mXdxQvarhq1LwTf2QozjukcfbYmyJLnmFLVdQJ4SRgHIRdT1yb7NJtlMCXAdewYVHktb2ac25XVLMpi65eQwKOyyGR142m-jHsP74SR_8U-2H5GqApyYATt1wn-wuFyv7iFw2n5ezatEhO8n4BJ-TxD1Fh-z1D4ejcced18Cv0dvj0WnHoc531EZ-1w |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3JbtQw1CoFARJiKVuggJFAbLI6kziJjYTQtKVq1UUIFdSbcWynHalNSmZKNXwU38Yn8J6TTEkRvfXA1Vts5y1-OyHPUDURisSwzIGsyrm0TCfaMS5c7KwGMNE-Zf5GurUldnbkxxnys42FQbfKliZ6Qm1LgzryBWCzvYjjC-H94TeGVaPQutqW0KjBYt1NjkFkG71bW4b_-zwMVz5sL62ypqoAM0kajRk-4J3sWdiRicJcGPRDB0lNhvCJVGbQxZ2NTRwZx3meulgamaTWOHhcOZ5EsO4FchHoeB9dyNJPX6ZWi1QkvLGc9kWyMAL-gFbSvmSRCCWbdHifLxHwNyP4gxOe9tI8Zar1HHDlxv92dzfJ9eatTQc1ctwiM66YI5c3G2-COXKt1lnSOhTrNvk1oLaEJsegubDU-6tlJWvc-fedpb7ICS1zqn8MscLEwQSWouOSVpgC19EDL82AZEM1LDD0GhtHd6vyeLxHYSRmh2bozk8nSGZpG0tPUR9Oi7JgPpJgQgFtq2qvdBpn7ZfH8IHazkJHzruqj95SeLvTQYFBPyUm26Ygf9ClzoLL01VeDhaXll81-8fkHCVQgDvk87nc_10yC0dx9wlNXC5kD9iLSQzacjMu8pynwuaRlv04C0ivhVVlmnTxWLVkX3mxUSSqBm8F4K0QvNUkIK-nUw7rXClnDV5EBJgOxDTnvqGsdlVDNZXNNNdCZrmLU65TqUNtMeoI7dk9q21AXiD6KCTGsDmjm5gSOCKmNVODBMQJLMDWC8h8ZyQQUdPtbjFHNUR8pE7QJiBPp904Ex0TC1cewZgIdgIiVtwPyL0aX6dHAu4GHJOLgKQdTO6cudtTDPd8ivdExhgEHpA3Lc6fbOufV_rg7EM8IVdWtzc31Mba1vpDcjVExRHQ5340T2bH1ZF7RC6Z7-PhqHrsqRolX8-bFPwG0Hbj0A |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3JbtQw1CotqpAQS9kCBYwEYlPUmcRZjITQdIYRVRfNoUjlZBzbaUdq45KZUg2fxlfxCbznJFNSRG89cPUW23mL307Ic1RNBGms_MyArMoY176MpfFZaiKjJYCJdCnzt5KdnXRvj48WyM8mFgbdKhua6Ai1tgp15GvAZjshwxfCWl67RYwGww_H33ysIIWW1qacRgUim2Z2CuLb5P3GAP71iyAYftztf_LrCgO-ipNw6uNj3vCOht2pMMhThT7pILXxAD6X8Ay6mNGRikJlGMsTE3HF40QrAw8tw-IQ1r1CluBJzgDHlkYb26MvcxtGksastqN203htAtwCbaZd7odpwP1ZixO6ggF_s4U_-OJ5n81zhlvHD4c3_-ebvEVu1K9w2qvQ5jZZMMUKWd6u_QxWyPVKm0mrIK075FePagtNxofmQlPnyZZZv3b0PzSauvIn1OZU_hhj7YmjGSxFp5aWmBzX0CMn54DMQyUsMHa6HEP3S3s6PaAwEvNG--joT2dIgGkTZU9RU04LW_guxmBGAaHL8sAaibMO7Sl8oLLA0IlxTuyTdxRe9bRXYDiQxTTcFCQT2m8tOJiv8qq33h-8rvePaTss0Ia75POl3P89sghHMQ8IjU2e8g4wHhUrtPJmLM1zlqQ6DyXvRplHOg3cClUnksd6JofCCZRpLCpQFwDqAkFdzDzyZj7luMqictHgdUSG-UBMgO4abLkvanoqdCaZTHmWmyhhMuEykBrjkdDS3dFSe-QlopJAMg2bU7KONoEjYsIz0YtB0MDSbB2PrLZGAnlV7e4Gi0RN3ifiDIU88mzejTPRZbEw9gTGhLATEL6irkfuV7g7PxLwPeClLPVI0sLq1pnbPcX4wCV_j3mE4eEeedvg_9m2_nmlDy8-xFOyDBRAbG3sbD4i1wLUKAHh7oarZHFanpjH5Kr6Ph1Pyic1iaPk62XTgt9LT-3z |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+double-blind+placebo-controlled+trial+of+azithromycin+to+reduce+mortality+and+improve+growth+in+high-risk+young+children+with+non-bloody+diarrhoea+in+low+resource+settings%3A+the+Antibiotics+for+Children+with+Diarrhoea+%28ABCD%29+trial+protocol&rft.jtitle=Trials&rft.date=2020-01-13&rft.pub=BioMed+Central&rft.eissn=1745-6215&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs13063-019-3829-y&rft.externalDocID=10_1186_s13063_019_3829_y |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |